Novartis India FY26 BRSR: Operational Metrics, Tax Disputes, and ESG Highlights
Novartis India Ltd 路 Others (Uncategorized) 路 02 Sept 2026, 10:38 pm
Novartis India FY26 BRSR: Operational Metrics, Tax Disputes, and ESG Highlights Novartis India reported FY26 (Apr'25-Mar'26) turnover of INR 3,543.4 Mn and net worth of INR 8,178.3 Mn from its pure-play pharma trading operations. Material contingencies include an appealed INR 33.83 Mn draft income tax order regarding transfer pricing and an INR 102.8 Mn TDS demand. Operationally, the firm recorded one forced product recall by Karnataka authorities. Environmentally, a strategic logistics shift from air to surface freight dramatically reduced Scope 2 emissions to 12.3 metric tonnes from 277.4 metric tonnes YoY. Zero data breaches were reported during the period.
Original exchange filing (PDF)
More announcements from Novartis India Ltd
- Transcript of the Earnings Call held on Wednesday, November 04, 2026. 路 06 Nov 2026
- Submission of the Letter of Offer in connection with the proposed Rights Issue of the Partly Paid-up Equity Shares of the Company. 路 06 Nov 2026
- Intimation is hereby given that the record date for determining the rights entitlement for the Rights Issue of partly paid-up shares of the Company shall be Wednesday, November 11, 2026. 路 05 Nov 2026
- Outcome of the Board Meeting held today i.e. November 04, 2026 路 05 Nov 2026
- Outcome of the meeting of the Rights Issue Committee held today i.e. November 04, 2026 路 05 Nov 2026
- Intimation of the Audio Recording of the Earnings Call for the Unaudited Financial Results for the quarter and half year ended September 30, 2026, held today i.e. on Wednesday, November 04, 2026. 路 04 Nov 2026
- Intimation of the Integrated Unaudited Financial Results for the quarter and half year ended September 30, 2026. 路 04 Nov 2026
- Press Release - Unaudited Financial Results for the quarter and half year ended September 30, 2026. 路 04 Nov 2026
